Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________________

FORM 8-K

_______________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 11, 2017

_______________________

LA JOLLA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

_______________________

California	1-36282	33-0361285
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

10182 Telesis Court, 6th Floor, San Diego, California 92121

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: [phone]

_______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see  General Instruction A.2. below):
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

ITEM 8.01    OTHER EVENTS.

On April 11, 2017, La Jolla Pharmaceutical Company (the "Company") made available on its website a copy of its investor presentation that includes an update on the Company's financial position to reflect its public offering of common stock announced March 20, 2017 and further background on its Phase 3 study of LJPC-501.  A copy of this presentation is filed herewith as Exhibit 99.1. The fact that this presentation is being made available and filed herewith should not be deemed an admission as to the materiality of any information contained in the materials. The information contained in the presentation is being provided as of April 11, 2017, and the Company does not undertake any obligation to update the presentation in the future.

ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits . The following exhibits are filed with this report on Form 8-K:

Exhibit No.		Description
99.1		La Jolla Pharmaceutical Company Corporate Presentation

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		La Jolla Pharmaceutical Company
Date:	April 11, 2017	/s/    Dennis M. Mulroy
		Dennis M. Mulroy
		Chief Financial Officer